Qingdao Vland Biotech Co Ltd (603739) — Working Capital to Net Assets Ratio
Qingdao Vland Biotech Co Ltd (603739) has a Working Capital to Net Assets ratio of 4.5% as of September 2025. Working capital of CN¥85.94 Million (current assets of CN¥1.15 Billion minus current liabilities of CN¥1.06 Billion) is measured against net assets of CN¥1.90 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Qingdao Vland Biotech Co Ltd to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Qingdao Vland Biotech Co Ltd Working Capital to Net Assets (2014–2024)
This chart shows how Qingdao Vland Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 4.5%, reflecting working capital of CN¥85.94 Million against net assets of CN¥1.90 Billion CNY. See 603739 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Qingdao Vland Biotech Co Ltd (2014–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Qingdao Vland Biotech Co Ltd from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Qingdao Vland Biotech Co Ltd worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 2.0% | CN¥37.75 Million | CN¥1.87 Billion | CN¥1.07 Billion | CN¥1.03 Billion | ▲ +0.1 pp |
| 2023 | 2.0% | CN¥35.77 Million | CN¥1.83 Billion | CN¥1.12 Billion | CN¥1.09 Billion | ▼ -16.7 pp |
| 2022 | 18.7% | CN¥324.31 Million | CN¥1.73 Billion | CN¥969.40 Million | CN¥645.09 Million | ▼ -16.9 pp |
| 2021 | 35.6% | CN¥599.50 Million | CN¥1.69 Billion | CN¥971.82 Million | CN¥372.33 Million | ▼ -6.5 pp |
| 2020 | 42.1% | CN¥469.43 Million | CN¥1.12 Billion | CN¥742.22 Million | CN¥272.80 Million | ▼ -8.5 pp |
| 2019 | 50.6% | CN¥522.13 Million | CN¥1.03 Billion | CN¥705.91 Million | CN¥183.78 Million | ▲ +17.6 pp |
| 2018 | 32.9% | CN¥207.94 Million | CN¥631.38 Million | CN¥460.49 Million | CN¥252.55 Million | ▼ -3.0 pp |
| 2017 | 35.9% | CN¥212.68 Million | CN¥592.53 Million | CN¥439.22 Million | CN¥226.55 Million | ▼ -0.8 pp |
| 2016 | 36.7% | CN¥204.99 Million | CN¥557.97 Million | CN¥406.57 Million | CN¥201.57 Million | ▲ +4.4 pp |
| 2015 | 32.3% | CN¥167.79 Million | CN¥519.36 Million | CN¥388.54 Million | CN¥220.74 Million | ▼ -3.5 pp |
| 2014 | 35.8% | CN¥167.14 Million | CN¥466.26 Million | CN¥395.02 Million | CN¥227.88 Million | — |